A pioneering clinical trial coordinated by Dr. Jordi Monfort at the Hospital del Mar, Barcelona, has proved that, unlike paracetamol, chondroitin sulfate reduces inflammation and improves functional capacity.
Professor Jean-Pierre Pelletier will present the results of a clinical trial which provides evidence that patients receiving chondroitin sulfate treatment experience a lower risk of having to endure prosthetic surgery.
• It is DNA-based test that, using a simple saliva simple, can identify certain genetic alterations associated to osteoarthritis progression.
• Dr. Vergés said that “this tool could be used to identify and to give personalized treatment to severe OA cases and to assess the risks of prosthetic surgery, which in turn will lead to significant savings in health care expenditure”.
This blog contains up-to-date information on osteoarthritis-treatment, publications, latest advances in research. It is also an online discussion area that encourages the participation of all healthcare professionals.
It is hosted in the condroprotection.es website, a dedicated portal for healthcare professionals who specialize in osteoarthritis.
Their new project focus on the research and validation of imaging and biochemical biomarkers used to diagnose knee osteoarthritis (OA) prior to the development of symptoms, to identify patient’s profiles, and to predict disease progression.
Biomarkers could be used to measure the efficacy of treatments, thus enabling the National Health System to save money.
The Foundation of the National Institutes of Health guarantees that the aim of this partnership is the improvement of the quality of life of OA patients by means of early diagnosis and personalized treatment.
* This website is not intended to report adverse events related to Bioiberica's products. If you would like to report a suspected adverse reaction, please contact the Department of Pharmacovigilance Bioiberica.